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Abstract 
Both types of diabetes mellitus (DM) are recognized by the destruction of pancreas or deficient 
function of Islets’ cells causing several complications. Diabetes mainly affect the kidney leading 
to diabetic nephropathy (DN) in the late renal stage, which caused higher mortality in diabetic 
patients. Since diabetic disease appearance, nephropathy may be observed in patients with type 1 
or 2 diabetes. Recently, cell culture can be used in the regenerative medicine as a new method 
for treating diabetes and DN. Therefore, the aim of the current study was to prove the beneficial 
effect of mesenchymal stromal cells (MSCs) transplantation on DN during the early stage. Male 
rats were randomized in 3 groups (each 20 rats): the 1st group was normal rats, while the 2nd was 
streptozotocin (STZ) diabetic rats and the 3rd was diabetic rats treated with a single intravenous 
dose of bone marrow mesenchymal stromal cells (BM-MSCs) after 3 days from STZ induction. 
Results indicated that STZ induced DN represented by weight loss, hyperglycemia, 
hypoinsulineamia, decreased glycated hemoglobin, leukocytosis and impairment of kidney 
function and oxidative stress in kidney tissue. After BM-MSCs treatment, blood glucose level 
was improved, renal function was retained, body weight loss was decreased, insulin level and 
HBA1C percent were ameliorated with improved oxidative stress in kidney tissue. BM-MSCs 
have the capacity to regenerate and differentiate into insulin- producing cells improving DM and 
DN. 
Keywords: Diabetic Nephropathy, Streptozotocin, Oxidative Stress, Bone-Marrow 
mesenchymal stromal cell. 
Introduction 
Diabetes mellitus is followed by several 
complications mainly diabetic nephropathy 
(DN) [1], which leads to renal disease in late 
stage and consequently increases both 
morbidity and mortality in diabetic cases [2,3]. 
Oxidative stress is a major factor in diabetic 
vascular complications including DN [4,5] as 
it leads to disturbance in the detoxification of 
reactive oxygen species (ROS) by the body 
which controls any damage. ROS regulates 
some genes and proteins that cause 
morphological and structural cell damage. 
Glycemic control may decrease the oxidative 
stress as it causes reduction of producing the 
intracellular reactive oxygen species [6]. 
Common therapies involve intensive control of 
hyperglycemia and hypertension but have no 
effect on diabetic nephropathy [7], so there is 
an important need to explore new method 
targeting DN. 
Stem cell therapy is used as a regenerative 
therapy in many diseases because of its self-
renewal and differentiation properties [8,9] 
thus, it has the potential to be more effective 
than other drug therapies [10]. The most 
available type of these cells is mesenchymal 
stromal cell (MSCs), which easily obtained 
from human (blood, dermis, bone, bone 
marrow, adipose tissue and muscles) and has 
the ability to differentiate into other tissues as 
muscle, fat, cartilage and bone [11-13]. In the 
current study, we aimed to investigate the 
pancreatic and renoprotective effects of 
autologous transplantation of mesenchymal 
stromal cells derived from bone marrow (BM) 
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in rats with streptozotocin (STZ) induced 
nephropathy. 
Material and Methods 
Experimental design 
The current study was carried out on 60 
male albino rats with body weight of 200±20g 
obtained from Standard Animal Laboratory 
Colony, Helwan, Cairo, Egypt. They were 
provided with ad libitum standard chow and 
water throughout the study. Rat model was 
performed by the Intra-peritoneal (IP) 
injection of 60 mg/kg STZ (Sigma–Aldrich, 
USA) [14] for the induction of type 1 and type 
2 diabetes. After 7 days for proliferation and 
following one night of fasting, diabetes was 
confirmed by measuring fasting blood sugar of 
reading >250 mg/dL for 3 continuous days. 
Male rats were divided into 3 groups (each 20 
rats): the 1st group was non-diabetic rats 
received only vehicle, while the 2nd group was 
rat of type 1 diabetes that induced by I/P 
injection of a single dose of STZ and not 
treated and the 3rd group was diabetic rats, 
which received intravenous injection (I.V) of 
BM-MSCs in a single dose of 106cells/rat in 1 
mL serum free medium (GIBCO) after 3 days 
from the induction of STZ. 
Culture, characterization and labeling of 
MSCs 
Bone marrow was collected and cultured 
for 14 days on Dulbiccos Modified Eagles 
Medium (DMEM) supplemented with 10 % 
fetal bovine serum after flushing the femurs 
and tibiae of 6 male rats [15]. MSCs were 
identified by their adhesiveness and fusiform 
shape. Red fluorescent cell linker (PKH26) 
was used in the labeling process [16] with 
transduction method (Sigma, Saint Louis, 
Missouri, USA) according to the 
manufacturer’s recommendations. 
Sample collection and analysis 
 Blood samples were collected for 
separation of serum from the retro-orbital 
venous sinus after 4 weeks from STZ injection 
for testing the biochemical parameters and 
blood samples for measuring hematological 
parameters. Kidneys were removed and 
divided into two parts; the first part was 
preserved frozen at –80 ◦C for estimating the 
oxidative stress markers and the other part of 
kidney was stored in 4% formalin for 
histopathological examination. Also, the 
pancreas was stored in 4% formalin for 
histopathological examination and 
immunohistochemical analysis. 
Fasting blood glucose levels were 
monitored along the experiment [17] while at 
the end of the experiment the glycosylated 
hemoglobin [18], insulin [19], creatinine [20] 
and urea [21] were estimated. On the day 27 
after MSCs injection (1 month from diabetes 
induction) and adaptation at early phase of 
diabetic nephropathy induced by STZ, rats 
were scarified and pancreas and kidney were 
removed for preparing paraffin block then 
stained by hematoxylin-eosin for 
histopathologic analysis under light 
microscope. PKH26 labeled MSCs were 
examined under fluorescence microscope [22]. 
An immunohistochemical staining on 4 µm 
frozen pancreatic sections was performed 
according to the streptavidin biotin peroxidase 
complex (ABC) method using primary Anti-
insulin antibody (guinea pig polyclonal to 
insulin, ab7842, Abcam, Cambridge, UK) and 
rabbit polyclonal secondary antibody (Rabbit 
polyclonal secondary antibody to guinea pig 
IgG - H&L Horse Radish Peroxidase (HRP), 
ab6771, Abcam, Cambridge, UK) on unstained 
positively charged slides from paraffin block 
[23].  Morphometric analysis was performed 
to measure the nuclear area and length of β-
cells of islet of pancreases using National 
Institute of Health (NIH) technique 1.60 
programs (NIH, Bethesda, Maryland, USA) 
[24]. The results were represented the 
effectiveness of the newly produced β-cells of 
pancreases. The malondialdehyde (MDA) 
content (thiobarbituric acid method [25]), the 
total superoxide dismutase (SOD) activity 
(xanthine oxidase method [26]) and reduced 
glutathione content of kidney homogenate 
(Ellman's method [27]) were measured with 
commercially available kits (Biodiagnostic Co. 
Cairo Egypt) 
Statistical analysis 
All data were represented by mean ± SE 
using Prism version 7 program. One-way 
ANOVA analysis was used to compare the 
different experimental groups.  
 
36 
Table 1: Effect of BM-MSCs on body weight, fasting blood sugar (FBS), glycated hemoglobin (HBA1C) and 
insulin in induced-diabetic rats (Mean±SE, N= 20) 
Group variables Control group DN group1 BM-MSCs group2 
Body weight (g) 303.3±8.5a 226.73± 6.93b 300.50± 12.57a 
FBS (mg/dL) 96.50± 2.63c 269± 28.01a 175.62± 7.11b 
HbA1C (%) 5.46± 0.30c 12.22± 0.23a 8.52± 0.33b 
Insulin (µ/g) 0.75±0.04a 0.2±0.021c 0.54±0.04b 
1DN group: rats of type 1 diabetes that induced by I/P injection of a single dose of STZ and not treated, 2BM-MSCs 
group: diabetic rats, which received intravenously injection of BM-MSCs in a single dose of 106cells/rat in 1 mL 
serum free medium (GIBCO) after 3 days from the induction of STZ. Means carrying different superscript within 
the same row were significant different at p < 0.05. 
Results and Discussion 
Four weeks after STZ injection, rats in the 
DN group showed light body weight and high 
blood sugar (P < 0.05) when compared with 
the non-diabetic group, while rats of the BM-
MSCs treated group revealed heavy body 
weight and low blood sugar (P < 0.05) when 
compared with the DN group (Table 1). 
Glycated hemoglobin showed a higher 
increase (P < 0.05) in the DN group when 
compared with the non-diabetic group, 
however it was significantly lower in the BM-
MSCs group when compared with the DN 
group. Moreover, insulin was significantly 
decreased in the DN group when compared 
with the control one, while, it showed 
ameliorative effect in the treated group 
compared with DN group (Table 1). The 
serum urea and creatinine levels in the DN rats 
were higher than the non-diabetic rats and 
their levels were significantly reduced after the 
injection of BM-MSCs when compared with 
DN group (Table 2). 
 
Table 2: Effect of BM-MSCs on renal functions and oxidative stress markers in the renal tissue of induced-
diabetic rats (Mean±SE, N= 20) 
Group variables Control group DN group1 BM-MSCs group2 
Urea (mg/dL) 45.57± 2.48c 93.48±7.19a 62.67± 2.17b 
Creatinine (mg/dL) 0.58±0.017c 2.78±0.22a 1.60±0.15b 
SOD (U/g)3 195.5±12.67a 105.67±4.62c 171.72±11.6b 
MDA (nmol/mg)4 1.78±0.28c 4.98±0.22a 3.2±0.22b 
GSH (U/g)5 33.03±2.97a 22.51±0.55b 25.15±0.65b 
1DN group: rats of type 1 diabetes that induced by I/P injection of a single dose of STZ and not treated, 2BM-MSCs 
group: diabetic rats, which received I.V injection of BM-MSCs in a single dose of 106cells/rat in 1 mL serum free 
medium (GIBCO) after 3 days from the induction of STZ. 3SOD: superoxide dismutase activity; 4MDA: 
malondialdehyde content; 5GSH: reduced glutathione content. Means carrying different superscript within the same 
row were significant different at p < 0.05. 
Our results suggested that, BM-MSCs was 
able to control the alteration of the oxidative 
stress in the kidney homogenate of diabetic 
rats where the treated group exhibited a 
significant increase (P < 0.05) in the SOD 
activity and the GSH concentrations when 
compared with the DN group. In addition, the 
MDA concentration showed a significant 
decrease (P < 0.05) in the BM-MSCs treated 
group when compared with DN group (Table 
2). These results were confirmed with the 
improvement in the histological examination 
of pancreas and kidney after BM-MSCs 
treatment (Figure 1).  As a result of 
immunohistochemical (IHC) examination, 
there was small islets regeneration in the BM-
MSCs treated group (Figure 2) confirmed by 
the improvement in insulin levels and blood 
glucose levels, which indicated the beneficial 
role of MSCs in amelioration of DN. The islets 
regeneration indicated also by morphometric 
analysis showed that the nuclear size and 
length of islet cell increased significantly after 
BM-MSCs transplantation when compared 
with the DN group (Table 3). 
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Table 3: Some nuclear morphometric features (Nuclear area and length) in different groups (Mean±SE, N= 
20) 
Morphometric feature Control group DN group1 BM-MSCs group2 
Nuclear area (µm2) 11.57± 3.61a 6.42 ± 2.71c 10.29 ± 4.41b 
Nuclear length (µm) 13.43 ± 2.10a 9.66 ± 0.2.29c 12.25 ± 2.85b 
1DN group: rats of type 1 diabetes that induced by I/P injection of a single dose of STZ and not treated, 2BM-MSCs 
group: diabetic rats, which received intravenously injection of BM-MSCs in a single dose of 106cells/rat in 1 mL 
serum free medium (GIBCO) after 3 days from the induction of STZ. Means carrying different superscript within 
the same row were significant different at p < 0.05. 
 
Supporting to our results, blood sugar 
was reduced by a single injection of MSCs 
in STZ- induced diabetic rats [28,29]. Also, 
the intravenous injection of adipose-derived 
mesenchymal stem cells (ADMSC) in 
diabetic mice could significantly decrease 
the fasting blood sugar level and increase 
the secretion of insulin in the islet β-cells 
[30]. A previous study was performed by 
Tsai et al. [31] who found that mesenchymal 
stem cells (MSCs) derived from the human 
bone marrow were differentiated into new 
pancreatic cells alleviated the increase in 
blood glucose in diabetic group. On similar 
ground, a streptozotocin (STZ) diabetic rat 
model treated with MSC injection at the 
early (7 days) and late phase (21 days) could 
be able to control the hyperglycemia in 
diabetic rats with type 2 [32]. Zhang, et al. 
[33] reported that the increased blood 
glucose was associated with the decreased 
insulin secretion in the diabetic rats when 
compared with the non-diabetic rats and it 
was improved after treated with MSCs, 
which represented by tubular dilatation, 
mesangial expansion and glomerular 
sclerosis observed histopathologically under 
light microscope. Similar to our result, Lee 
et al. [34] and Ezquer et al. [35] showed that 
hyperglycemia and renal histology of 
diabetic rat was improved by MSC therapy 
when compared with the DN group. Lang 
and Dai [36] study showed that, there was 
an increase in the mesangial cells and 
mesangial matrix in diabetic rats when 
compared with the non-diabetic rats whereas 
in the MSC group, the histopathological 
changes were improved inhibiting the renal 
fibrosis compared with the DN group. 
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Figure 1: A- Normal pancreatic section from the control group (H&E X 360), B-  The DN group showed 
necrotic Islets’ cells of pancreas and marked edema (H&E X360), C- The BM-MSCs treated group showed 
more cellular Islets of pancreas (H&E X 360), D- Normal kidney section from the control group (H & E X 
360), E- The DN group showed markedly dilated congested blood vessel in the kidney (H & E X 360), F- The 
BM-MSCs treated group showed average glomerulus and tubules in the kidney  (H & E X 360). 
 
 
Figure 2: A- Normal pancreatic section from the control group showed marked cytoplasmic reactivity to 
insulin antibodies (insulin immunostain x 360). B- The DN group showed mild cytoplasmic reactivity to 
insulin antibodies (insulin immunostain x 360). C- The BM-MSCs treated group showed marked reactivity to 
insulin antibodies (insulin immunostain x 360). 
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Serum urea and creatinine were lowered 
after the BM-MSCs treatment due to the 
decrease protein degradation and the increase 
of their clearance by the kidney [37]. In 
contrary with our study, compared with the 
DN group, the single transplantation of MSCs 
didn't affect blood glucose levels in diabetic 
rats, whereas repeated injection for 7 days 
could significantly control it [38]. Moreover, a 
study of Ezquer et al. [39] demonstrated that, 
administration of MSCs in a mouse model did 
not result in hyperglycemia correction. In 
addition, Wang et al. [12] provided clear 
evidence that the injected MSCs prevented the 
development of albuminuria and loss of 
podocytes but there was no improvement in 
blood sugar levels. MSCs was used to 
ameliorate hyperglycemia, suppress oxidative 
stress in kidney homogenate and improve renal 
histopathological changes in diabetic rats with 
DN [40]. Liu et al. [41] reported that the IHC 
of the DN group showed mild cytoplasmic 
reactivity to insulin antibodies when compared 
with the control group and after treated with 
BM-MSCs, the pancreatic tissue showed 
marked reactivity to insulin antibodies (more 
than 75% of Islets’ cells) when compared with 
the DN group, which supported our findings.  
Conclusion 
Bone marrow mesenchymal stromal cells 
had the ability to renew into islet cells and   
were differentiated into functional insulin 
secreting cells, which indicated its beneficial 
effects on diabetes-induced nephropathy and 
strongly recommended BM-MSCs in treating 
clinical cases of DM and DN as a future 
therapy. 
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 العربي الملخص
 اعتلال الكلي السكري في ذكور الجرذان التأثير المحسن للخلايا الجذعية الوسيطه علي
 
 *3انجي محمد محمد ياسينو 2حمد أمين السعداوي،2حسين ابراهيم البلبيسي،1أحمد ابراهيم منصور
 جامعة الأزهر -)بنين(قسم الادويه والسموم كلية الصيدلة 1
 جامعة الزقازيق -كلية  الطب البيطري قسم الكيمياء الحيوية2
  جامعة الزقازيق -قسم الكيمياء الحيوية كلية العلوم3
 
مرض  .او الاعتلال الوظيفي لخلايا ايلتز مما يتسبب في مضاعفات عديدةالبنكرياس  يتميز بتدميرالسكري  كلا نوعي مرض
اعتلال الكلية السكري في المراحل المتأخرة، مما يتسبب في ارتفاع معدل الوفيات بشكل رئيسي على الكلى مما يؤدي إلى  السكري يؤثر
 من مرض السكري. 2أو  1في مرضى السكري. منذ ظهور مرض السكري، قد لوحظ اعتلال الكلية في المرضى الذين يعانون من نوع 
من افضل انواع الخلايا  يا الجذعية الوسيطةه وتعتبر الخلاعلاج امن وفعال للسكري ومضاعفات زراعة الخلايا الجذعيةويعد 
المعزولة من النخاع  ار تاثير الخلايا الجذعية الوسيطهالجذعية لتحسين نسبة السكر بالدم. لذلك الهدف من هذه الدراسة اظه
(كل مجموعه، الاعتلال الكلوي خلال المراحل المبكره. تم التقسيم العشوائي لذكور الجرزان الي ثلاث مجموعات الشوكي علي 
مصابه بالسكري نتيجه للحقن المجموعه الثانيه كانت تحتوي علي جرزان  ): المجموعه الأولي كانت جرذان طبيعية بينما02
والمحموعة الثالثة تحتوي علي جرذان مصابة بالسكري ومعالجه بحقن في الوريد بالخلايا الجذعيه  nicotozotpertsبمادة 
أظهرت النتائج ان الجرذان المصابه بالاعتلال الكلوي .  ZTSالشوكي بعد ثلاث ايام من تحفيز  الوسيطه المعزولة من النخاع
ظهر فيها فقدان للوزن، ارتفاع في مستوي السكر في الدم، انخفاض في الانسولين، انخفاض في  ZTSالذي حدث نتيجة 
وبعد العلاج  الكلى والإجهاد التأكسدي في أنسجة الكلى. زيادة عدد الكريات البيضاء وانخفاض في وظائفالهيموجلوبين الجلكاتين، 
في الدم ووظائف الكلي، تم تخفيض فقدان وزن الجسم وتحسن في السكر  مستوي ن فيتحس لوحظاالجذعية  الخلايا بإستخدام 
 النخاع الشوكيالخلايا الجذعية الوسيطه المعزولة من مع تحسن الأكسدة في نسيج الكلي.  1CABHمستوي الانسولين ونسبة 
 لديها القدرة علي تجديد وتفريق الخلايا المنتجة للانسولين مما يؤدي الي تحسن مرض السكري والاعنلال الكلوي.
 
 
